...
首页> 外文期刊>Neuropathology: official journal of the Japanese Society of Neuropathology >Immunohistochemical characterization of CD33 expression on microglia in Nasu-Hakola disease brains
【24h】

Immunohistochemical characterization of CD33 expression on microglia in Nasu-Hakola disease brains

机译:Nasu-Hakola病脑小胶质细胞CD33表达的免疫组织化学表征

获取原文
获取原文并翻译 | 示例
           

摘要

Nasu-Hakola disease (NHD) is a rare autosomal recessive disorder, characterized by formation of multifocal bone cysts and development of leukoencephalopathy, caused by genetic mutations of either DNAX-activation protein 12 (DAP12) or triggering receptor expressed on myeloid cells 2 (TREM2). Although increasing evidence suggests a defect in microglial TREM2/DAP12 function in NHD, the molecular mechanism underlying leukoencephalopathy with relevance to microglial dysfunction remains unknown. TREM2, by transmitting signals via the immunoreceptor tyrosine-based activation motif (ITAM) of DAP12, stimulates phagocytic activity of microglia, and ITAM signaling is counterbalanced by sialic acid-binding immunoglobulin (Ig)-like lectins (Siglecs)-mediated immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling. To investigate a role of CD33, a member of the Siglecs family acting as a negative regulator of microglia activation, in the pathology of NHD, we studied CD33 expression patterns in five NHD brains and 11 controls by immunohistochemistry. In NHD brains, CD33 was identified exclusively on ramified and amoeboid microglia accumulated in demyelinated white matter lesions but not expressed in astrocytes, oligodendrocytes, or neurons. However, the number of CD33-immunoreactive microglia showed great variability from case to case and from lesion to lesion without significant differences between NHD and control brains. These results do not support the view that CD33-expressing microglia play a central role in the development of leukoencephalopathy in NHD brains.
机译:Nasu-Hakola病(NHD)是一种罕见的常染色体隐性遗传疾病,其特征在于多灶性骨囊肿的形成和白质脑病的发展,这是由DNAX激活蛋白12(DAP12)或在髓样细胞2(TREM2)上表达的触发受体的基因突变引起的)。尽管越来越多的证据表明NHD中小胶质细胞TREM2 / DAP12功能存在缺陷,但与小胶质细胞功能障碍相关的白质脑病的分子机制仍然未知。 TREM2通过DAP12的基于免疫受体酪氨酸的激活基序(ITAM)传递信号,刺激小胶质细胞的吞噬活性,而ITAM信号被唾液酸结合免疫球蛋白(Ig)样凝集素(Siglecs)介导的免疫受体酪氨酸抑制。抑制基序(ITIM)信号。为了研究CD33(作为Siglecs家族成员的小胶质细胞激活的负调节剂)在NHD病理中的作用,我们通过免疫组织化学研究了五个NHD大脑和11个对照中的CD33表达模式。在NHD大脑中,CD33仅在脱髓鞘的白质损伤中积累的分支和变形虫小胶质细胞上被鉴定,而在星形胶质细胞,少突胶质细胞或神经元中不表达。但是,CD33免疫反应性小胶质细胞的数量在不同病例之间和不同病灶之间表现出很大的变异性,而NHD与对照脑之间无明显差异。这些结果不支持这样的观点,即表达CD33的小胶质细胞在NHD脑白细胞性脑病的发展中起着中心作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号